39 related articles for article (PubMed ID: 16474072)
1. Usher syndrome IIIA: a review of the disorder and preclinical research advances in therapeutic approaches.
Marouf A; Johnson B; Alagramam KN
Hum Genet; 2022 Apr; 141(3-4):759-783. PubMed ID: 35320418
[TBL] [Abstract][Full Text] [Related]
2. The Ototoxicity of Antimalarial Drugs-A State of the Art Review.
Jozefowicz-Korczynska M; Pajor A; Lucas Grzelczyk W
Front Neurol; 2021; 12():661740. PubMed ID: 33959089
[TBL] [Abstract][Full Text] [Related]
3. Cerebral Malaria: Hear before Discharge!
Joshi A; Gupta N; Ish P; Chakrabarti S
Indian J Crit Care Med; 2020 Mar; 24(3):212-213. PubMed ID: 32435105
[No Abstract] [Full Text] [Related]
4. Artemisinins-a Promising New Treatment for Systemic Lupus Erythematosus: a Descriptive Review.
Mu X; Wang C
Curr Rheumatol Rep; 2018 Jul; 20(9):55. PubMed ID: 30056574
[TBL] [Abstract][Full Text] [Related]
5. Severe malaria in children leads to a significant impairment of transitory otoacoustic emissions--a prospective multicenter cohort study.
Schmutzhard J; Lackner P; Helbok R; Hurth HV; Aregger FC; Muigg V; Kegele J; Bunk S; Oberhammer L; Fischer N; Pinggera L; Otieno A; Ogutu B; Agbenyega T; Ansong D; Adegnika AA; Issifou S; Zorowka P; Krishna S; Mordmüller B; Schmutzhard E; Kremsner P
BMC Med; 2015 May; 13():125. PubMed ID: 26021376
[TBL] [Abstract][Full Text] [Related]
6. Neuroauditory toxicity of artemisinin combination therapies-have safety concerns been addressed?
Ramos-Martín V; González-Martínez C; Mackenzie I; Schmutzhard J; Pace C; Lalloo DG; Terlouw DJ
Am J Trop Med Hyg; 2014 Jul; 91(1):62-73. PubMed ID: 24865683
[TBL] [Abstract][Full Text] [Related]
7. Reversible audiometric threshold changes in children with uncomplicated malaria.
Adjei GO; Goka BQ; Kitcher E; Rodrigues OP; Badoe E; Kurtzhals JA
J Trop Med; 2013; 2013():360540. PubMed ID: 23554819
[TBL] [Abstract][Full Text] [Related]
8. Randomized, prospective, three-arm study to confirm the auditory safety and efficacy of artemether-lumefantrine in Colombian patients with uncomplicated Plasmodium falciparum malaria.
Carrasquilla G; Barón C; Monsell EM; Cousin M; Walter V; Lefèvre G; Sander O; Fisher LM
Am J Trop Med Hyg; 2012 Jan; 86(1):75-83. PubMed ID: 22232454
[TBL] [Abstract][Full Text] [Related]
9. Probability of emergence of antimalarial resistance in different stages of the parasite life cycle.
Pongtavornpinyo W; Hastings IM; Dondorp A; White LJ; Maude RJ; Saralamba S; Day NP; White NJ; Boni MF
Evol Appl; 2009 Feb; 2(1):52-61. PubMed ID: 20526409
[TBL] [Abstract][Full Text] [Related]
10. Artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria.
Ehrhardt S; Meyer CG
Ther Clin Risk Manag; 2009; 5():805-15. PubMed ID: 19851528
[TBL] [Abstract][Full Text] [Related]
11. Discovery, mechanisms of action and combination therapy of artemisinin.
Cui L; Su XZ
Expert Rev Anti Infect Ther; 2009 Oct; 7(8):999-1013. PubMed ID: 19803708
[TBL] [Abstract][Full Text] [Related]
12. Auditory assessment of patients with acute uncomplicated Plasmodium falciparum malaria treated with three-day mefloquine-artesunate on the north-western border of Thailand.
Carrara VI; Phyo AP; Nwee P; Soe M; Htoo H; Arunkamomkiri J; Singhasivanon P; Nosten F
Malar J; 2008 Nov; 7():233. PubMed ID: 18986553
[TBL] [Abstract][Full Text] [Related]
13. Ototoxicity of artemether/lumefantrine in the treatment of falciparum malaria: a randomized trial.
Gürkov R; Eshetu T; Miranda IB; Berens-Riha N; Mamo Y; Girma T; Krause E; Schmidt M; Hempel JM; Löscher T
Malar J; 2008 Sep; 7():179. PubMed ID: 18796142
[TBL] [Abstract][Full Text] [Related]
14. Safety and tolerability of combination antimalarial therapies for uncomplicated falciparum malaria in Ugandan children.
Maiteki-Sebuguzi C; Jagannathan P; Yau VM; Clark TD; Njama-Meya D; Nzarubara B; Talisuna AO; Kamya MR; Rosenthal PJ; Dorsey G; Staedke SG
Malar J; 2008 Jun; 7():106. PubMed ID: 18547415
[TBL] [Abstract][Full Text] [Related]
15. A case-control auditory evaluation of patients treated with artemether-lumefantrine.
Hutagalung R; Htoo H; Nwee P; Arunkamomkiri J; Zwang J; Carrara VI; Ashley E; Singhasivanon P; White NJ; Nosten F
Am J Trop Med Hyg; 2006 Feb; 74(2):211-4. PubMed ID: 16474072
[TBL] [Abstract][Full Text] [Related]
16. No hearing loss associated with the use of artemether-lumefantrine to treat experimental human malaria.
McCall MB; Beynon AJ; Mylanus EA; van der Ven AJ; Sauerwein RW
Trans R Soc Trop Med Hyg; 2006 Dec; 100(12):1098-104. PubMed ID: 16808940
[TBL] [Abstract][Full Text] [Related]
17. Effects of weight, age, and time on artemether-lumefantrine associated ototoxicity and evidence of irreversibility.
Toovey S
Travel Med Infect Dis; 2006 Mar; 4(2):71-6. PubMed ID: 16887727
[TBL] [Abstract][Full Text] [Related]
18. Artemether + lumefantrine: new drug. An alternative to atovaquone + proguanil.
Prescrire Int; 2008 Apr; 17(94):54-6. PubMed ID: 18516806
[TBL] [Abstract][Full Text] [Related]
19. Artemether-lumefantrine: an oral antimalarial for uncomplicated malaria in children.
Adjei GO; Goka BQ; Binka F; Kurtzhals JA
Expert Rev Anti Infect Ther; 2009 Aug; 7(6):669-81. PubMed ID: 19681693
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
